Is Design Therapeutics, Inc. (DSGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 42.9% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 42.9% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.9% / 33% | 97.4% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 42.9% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.9% / 33% | 97.4% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -30.7% | |
| Return on Assets (ROA) | -20.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$43M |
| Free Cash Flow | -$43M |
| Total Debt | $2M |
| Debt-to-Equity | 0.7 |
| Current Ratio | 17.1 |
| Total Assets | $252M |
Price & Trading
| Last Close | $10.71 |
| 50-Day MA | $10.25 |
| 200-Day MA | $7.34 |
| Avg Volume | 278K |
| Beta | 1.6 |
|
52-Week Range
$2.60
| |
About Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Design Therapeutics, Inc. (DSGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Design Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Design Therapeutics, Inc.'s debt ratio?
Design Therapeutics, Inc.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.9%.
What are Design Therapeutics, Inc.'s key financial metrics?
Design Therapeutics, Inc. has a market capitalization of $649M. Return on equity stands at -30.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.